FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Mark Nelson

Research Profile

Disorders

Anatomy

Chemicals & Drugs

Physiology

Co-author Network

Publications

TOP 3
Alysia N Lozano-Ondoua; Patrick W Mantyh; Mark A Nelson; Tijana Nikolich-Zugich; Mabel Owusu-Ankomah; Frank Porreca; Ashley M Symons-Liguori; Aaron P Bloom; Anupama Chandramouli; Henry L Ferland; Katherine E Hanlon; Josh J Havelin; Juan Miguel Jimenez-Andrade; Tamara King; Tally M Largent-Milnes; Todd W Vanderah
Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.
Anupama Chandramouli; Ronald L Heimark; Bonnie J LaFleur; Melania Mercado-Pimentel; Benjamin Chidi Onyeagucha; Nisreen Abu Shahin; Lenka Stankova; Achyut K Bhattacharyya; Mark A Nelson
MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers.
Devki Sukhtankar; Todd W Vanderah; Anupama Chandramouli; Anne E Cress; Mark A Nelson; Alec Okun; Frank Porreca; Tamara King
Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Mark Nelson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Alysia N Lozano-Ondoua; Patrick W Mantyh; Mark A Nelson; Tijana Nikolich-Zugich; Mabel Owusu-Ankomah; Frank Porreca; Ashley M Symons-Liguori; Aaron P Bloom; Anupama Chandramouli; Henry L Ferland; Katherine E Hanlon; Josh J Havelin; Juan Miguel Jimenez-Andrade; Tamara King; Tally M Largent-Milnes; Todd W Vanderah
Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists.
Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research 2013;28(1):92-107.
2012: Anupama Chandramouli; Ronald L Heimark; Bonnie J LaFleur; Melania Mercado-Pimentel; Benjamin Chidi Onyeagucha; Nisreen Abu Shahin; Lenka Stankova; Achyut K Bhattacharyya; Mark A Nelson
MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers.
Cancer biology & therapy 2012;13(3):175-83.
2011: Devki Sukhtankar; Todd W Vanderah; Anupama Chandramouli; Anne E Cress; Mark A Nelson; Alec Okun; Frank Porreca; Tamara King
Inhibition of p38-MAPK signaling pathway attenuates breast cancer induced bone pain and disease progression in a murine model of cancer-induced bone pain.
Molecular pain 2011;7():81.
2010: Anupama Chandramouli; Melania Mercado-Pimentel; Anthony Hutchinson; Adriana Gibadulinová; Erik R Olson; Sally Dickinson; Reneé Shañas; Jennifer Davenport; Janae Owens; Achyut K Bhattacharyya; John W Regan; Silvia Pastorekova; Thiruvengadam Arumugam; Craig D Logsdon; Mark A Nelson
The induction of S100p expression by the Prostaglandin E₂ (PGE₂)/EP4 receptor signaling pathway in colon cancer cells.
Cancer biology & therapy 2010;10(10):1056-66.
2009: Jiaqi Shi; John W B Hershey; Mark A Nelson
Phosphorylation of the eukaryotic initiation factor 3f by cyclin-dependent kinase 11 during apoptosis.
FEBS letters 2009;583(6):971-7.
2008: Adriana Doldan; Anupama Chandramouli; Reneé Shanas; Achyut Bhattacharyya; Stanley P L Leong; Mark A Nelson; Jiaqi Shi
Loss of the eukaryotic initiation factor 3f in melanoma.
Molecular carcinogenesis 2008;47(10):806-13.
2008: Durga P Cherukuri; Mark A Nelson
Role of reactive oxygen species (ROS) and JNKs in selenite-induced apoptosis in HepG2 cells.
Cancer biology & therapy 2008;7(5):697-8.
2008: Adriana Doldan; Anupama Chandramouli; Reneé Shanas; Achyut Bhattacharyya; John T Cunningham; Mark A Nelson; Jiaqi Shi
Loss of the eukaryotic initiation factor 3f in pancreatic cancer.
Molecular carcinogenesis 2008;47(3):235-44.
2007: George S Watts; Nhan L Tran; Michael Berens; Achyut K Bhattacharyya; Mark A Nelson; Elizabeth Montgomery; Richard E Sampliner
Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma.
International journal of cancer. Journal international du cancer 2007;121(10):2132-9.
2007: Anupama Chandramouli; Jiaqi Shi; Yongmei Feng; Hana Holubec; Renée M Shanas; Achyut K Bhattacharyya; Wenxin Zheng; Mark A Nelson
Haploinsufficiency of the cdc2l gene contributes to skin cancer development in mice.
Carcinogenesis 2007;28(9):2028-35.
2007: Durga P Cherukuri; Xiao-bo Chen; Anne-Christine Goulet; Robert N Young; Yongxin Han; Ronald L Heimark; John W Regan; Emmanuelle J Meuillet; Mark A Nelson
The EP4 receptor antagonist, L-161,982, blocks prostaglandin E2-induced signal transduction and cell proliferation in HCA-7 colon cancer cells.
Experimental cell research 2007;313(14):2969-79.
2007: Anne-Christine Goulet; George Watts; Jean L Lord; Mark A Nelson
Profiling of selenomethionine responsive genes in colon cancer by microarray analysis.
Cancer biology & therapy 2007;6(4):494-503.
2007: Mark A Nelson
Inhibition of lipoxygenase activity: implications for the treatment and chemoprevention of prostate cancer.
Cancer biology & therapy 2007;6(2):237.
2006: Jiaqi Shi; A Kahle; J W B Hershey; B M Honchak; James Warneke; S P L Leong; Mark A Nelson
Decreased expression of eukaryotic initiation factor 3f deregulates translation and apoptosis in tumor cells.
Oncogene 2006;25(35):4923-36.
2006: Mark A Nelson; Steven H Reynolds; Uma N M Rao; Anne-Christine Goulet; Yongmei Feng; Anthony Beas; Barbara Honchak; Jim Averill; David T Lowry; Jamie Senft; Amy M Jefferson; Robert C Johnson; Linda M Sargent
Increased gene copy number of the transcription factor E2F1 in malignant melanoma.
Cancer biology & therapy 2006;5(4):407-12.
2005: Yongmei Feng; Maria-Eugenia Ariza; Anne-Christine Goulet; Jiaqi Shi; Mark A Nelson
Death-signal-induced relocalization of cyclin-dependent kinase 11 to mitochondria.
The Biochemical journal 2005;392(Pt 1):65-73.
2005: Mark A Nelson; Anne-Christine Goulet; Elizabeth T Jacobs; Peter Lance
Studies into the anticancer effects of selenomethionine against human colon cancer.
Annals of the New York Academy of Sciences 2005;1059():26-32.
2005: Jiaqi Shi; Mark A Nelson
The cyclin-dependent kinase 11 interacts with NOT2.
Biochemical and biophysical research communications 2005;334(4):1310-6.
2005: Durga P Cherukuri; Mark A Nelson
Could the combination of celecoxib and 4HPR be an effective lung cancer treatment?
Cancer biology & therapy 2005;4(8):899-900.
2005: Yongmei Feng; Wenqing Qi; Jesse D Martinez; Mark A Nelson
The cyclin-dependent kinase 11 interacts with 14-3-3 proteins.
Biochemical and biophysical research communications 2005;331(4):1503-9.
2005: Adrian Brunkhorst; Mattias Karlén; Jiaqi Shi; Monika Mikolajczyk; Mark A Nelson; Madis Metsis; Ola Hermanson
A specific role for the TFIID subunit TAF4 and RanBPM in neural progenitor differentiation.
Molecular and cellular neurosciences 2005;29(2):250-8.
2005: Durga P Cherukuri; Anne-Christine Goulet; Hiroyasu Inoue; Mark A Nelson
Selenomethionine regulates cyclooxygenase-2 (COX-2) expression through nuclear factor-kappa B (NF-kappaB) in colon cancer cells.
Cancer biology & therapy 2005;4(2):175-80.
2005: Amy Christine Baruch; Jiaqi Shi; Yongmei Feng; Mark A Nelson
New developments in the staging of melanoma.
Cancer investigation 2005;23(6):561-7.
2005: Anne-Christine Goulet; Marianne Chigbrow; Peter Frisk; Mark A Nelson
Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells.
Carcinogenesis 2005;26(1):109-17.
2004: Monika Mikolajczyk; Mark A Nelson
Regulation of stability of cyclin-dependent kinase CDK11p110 and a caspase-processed form, CDK11p46, by Hsp90.
The Biochemical journal 2004;384(Pt 3):461-7.
2004: Durga P Cherukuri; Mark A Nelson
Do elevated levels of eicosanoids play a role in head and neck cancer recurrence and metastasis? Implications for prevention and treatment.
Cancer biology & therapy 2004;3(9):853-4.
2004: Yongmei Feng; Anne-Christine Goulet; Mark A Nelson
Identification and characterization of the human Cdc2l2 gene promoter.
Gene 2004;330():75-84.
2004: Emmanuelle J Meuillet; Suzanne Stratton; Durga Prasad Cherukuri; Anne-Christine Goulet; Jacob Kagey; Bruce Porterfield; Mark A Nelson
Chemoprevention of prostate cancer with selenium: an update on current clinical trials and preclinical findings.
Journal of cellular biochemistry 2004;91(3):443-58.
2004: Durga P Cherukuri; Mark A Nelson
Glioma growth inhibition by selective COX-2 inhibitors via cyclooxygenase independent pathways: implications for therapy.
Cancer biology & therapy 2004;3(1):63-4.
2003: Anne-Christine Goulet; Janine G Einsphar; David S Alberts; Anthony Beas; Cynthia Burk; Achyut Bhattacharyya; Jerry Bangert; Janet M Harmon; Hideji Fujiwara; Alane T Koki; Mark A Nelson
Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression.
Cancer biology & therapy 2003;2(6):713-8.
2003: Jiaqi Shi; Yongmei Feng; Anne-Christine Goulet; Richard R Vaillancourt; Nancy A Sachs; John W Hershey; Mark A Nelson
The p34cdc2-related cyclin-dependent kinase 11 interacts with the p47 subunit of eukaryotic initiation factor 3 during apoptosis.
The Journal of biological chemistry 2003;278(7):5062-71.
2002: Antonio Baines; Michele Taylor-Parker; Anne-Christine Goulet; Christian Renaud; Eugene W Gerner; Mark A Nelson
Selenomethionine inhibits growth and suppresses cyclooxygenase-2 (COX-2) protein expression in human colon cancer cell lines.
Cancer biology & therapy 2002;1(4):370-4.
2002: Mark A Nelson; Mary Reid; Anna J Duffield-Lillico; James R Marshall
Prostate cancer and selenium.
The Urologic clinics of North America 2002;29(1):67-70.
2002: Janine G Einspahr; Mark A Nelson; Kathylynn Saboda; James Warneke; George Bowden; David S Alberts
Modulation of biologic endpoints by topical difluoromethylornithine (DFMO), in subjects at high-risk for nonmelanoma skin cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):149-55.
2001: Michael D Radmacher; R Simon; Richard Desper; Raymond M Taetle; Alejandro A Schäffer; Mark A Nelson
Graph models of oncogenesis with an application to melanoma.
Journal of theoretical biology 2001;212(4):535-48.
2001: Linda M Sargent; Mark A Nelson; D T Lowry; Jamie Senft; A M Jefferson; Maria-Eugenia Ariza; Steven H Reynolds
Detection of three novel translocations and specific common chromosomal break sites in malignant melanoma by spectral karyotyping.
Genes, chromosomes & cancer 2001;32(1):18-25.
2000: Antonio Baines; Hana Holubec; JL Basye; P Thorne; Achyut K Bhattacharyya; Julian E Spallholz; B Shriver; Haiyan Cui; Denise Roe; Larry C Clark; David L Earnest; Mark A Nelson
The effects of dietary selenomethionine on polyamines and azoxymethane-induced aberrant crypts.
Cancer letters 2000;160(2):193-8.
2000: Mark A Nelson; Michael D Radmacher; R Simon; Mikel Aickin; J Yang; L Panda; JC Emerson; D Roe; L Adair; F Thompson; Jerry Bangert; S P Leong; Raymond M Taetle; Sydney E Salmon; Jeffrey M. Trent
Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases.
Cancer genetics and cytogenetics 2000;122(2):101-9.
1999: Janine G Einspahr; David S Alberts; James Warneke; Paul Bozzo; JL Basye; T M Grogan; Mark A Nelson; George Bowden
Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis.
Neoplasia (New York, N.Y.) 1999;1(5):468-75.
1999: Maria-Eugenia Ariza; M Broome-Powell; Jill Lahti; Vincent J Kidd; Mark A Nelson
Fas-induced apoptosis in human malignant melanoma cell lines is associated with the activation of the p34(cdc2)-related PITSLRE protein kinases.
The Journal of biological chemistry 1999;274(40):28505-13.
1999: Mark A Nelson; B W Porterfield; Elizabeth T Jacobs; Larry C Clark
Selenium and prostate cancer prevention.
Seminars in urologic oncology 1999;17(2):91-6.
1999: Mark A Nelson; Maria-Eugenia Ariza; JM Yang; FH Thompson; Raymond M Taetle; Jeffrey M. Trent; J Wymer; KS Massey-Brown; M Broome-Powell; J Easton; Jill Lahti; Vincent J Kidd
Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
Cancer genetics and cytogenetics 1999;108(2):91-9.
1998: C Redman; J A Scott; Antonio Baines; JL Basye; Larry C Clark; C Calley; Denise Roe; Claire M Payne; Mark A Nelson
Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines.
Cancer letters 1998;125(1-2):103-10.
1997: J H Barks; FH Thompson; Raymond M Taetle; JM Yang; JF Stone; J A Wymer; R Khavari; XY Guan; Jeffrey M. Trent; D Pinkel; Mark A Nelson
Increased chromosome 20 copy number detected by fluorescence in situ hybridization (FISH) in malignant melanoma.
Genes, chromosomes & cancer 1997;19(4):278-85.
1997: FH Thompson; Raymond M Taetle; Jeffrey M. Trent; Y Liu; KS Massey-Brown; Katherine M Scott; Ronald S Weinstein; JC Emerson; David S Alberts; Mark A Nelson
Band 1p36 abnormalities and t(1;17) in ovarian carcinoma.
Cancer genetics and cytogenetics 1997;96(2):106-10.
1997: C Redman; Min-Jian Xu; Yei-Mei Peng; J A Scott; Claire M Payne; Larry C Clark; Mark A Nelson
Involvement of polyamines in selenomethionine induced apoptosis and mitotic alterations in human tumor cells.
Carcinogenesis 1997;18(6):1195-202.
1996: Mark A Nelson; F H Thompson; JC Emerson; Mikel Aickin; L Adair; Jeffrey M. Trent; S P Leong; Raymond M Taetle
Clinical implications of cytogenetic abnormalities in melanoma.
The Surgical clinics of North America 1996;76(6):1257-71.
1996: Mark A Nelson; J Wymer; N Clements
Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers.
Cancer letters 1996;103(1):115-21.
1996: F H Thompson; Mark A Nelson; Jeffrey M. Trent; XY Guan; Y Liu; JM Yang; JC Emerson; L Adair; J Wymer; Celia A Balfour; K Massey; R Weinstein; D S Alberts; Raymond M Taetle
Amplification of 19q13.1-q13.2 sequences in ovarian cancer. G-band, FISH, and molecular studies.
Cancer genetics and cytogenetics 1996;87(1):55-62.
1995: N C Clements; Mark A Nelson; J A Wymer; C Savage; M Aguirre; Harinder Garewal
Analysis of K-ras gene mutations in malignant and nonmalignant endobronchial tissue obtained by fiberoptic bronchoscopy.
American journal of respiratory and critical care medicine 1995;152(4 Pt 1):1374-8.
1995: F H Thompson; JC Emerson; S Olson; R Weinstein; S A Leavitt; S P Leong; Scott S Emerson; Jeffrey M. Trent; Mark A Nelson; Sydney E Salmon
Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes.
Cancer genetics and cytogenetics 1995;83(2):93-104.
1994: Mark A Nelson; Janine G Einspahr; D S Alberts; Celia A Balfour; J A Wymer; K L Welch; Stuart Salasche; Jerry Bangert; Thomas M Grogan; Paul Bozzo
Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers.
Cancer letters 1994;85(1):23-9.
1994: A Leibovitz; J Wymer; K Massey; F H Thompson; Mark A Nelson
Establishment of a new lung sarcoma cell line from a human lung carcinosarcoma.
Cancer letters 1994;82(2):145-52.
1993: Mark A Nelson; F E Domann; George Bowden; Stephen B Hooser; Quintus Fernando; Dean E Carter
Effects of acute and subchronic exposure of topically applied fullerene extracts on the mouse skin.
Toxicology and industrial health 1993;9(4):623-30.
1992: Mark A Nelson; Bernard W Futscher; M R Loew; George Bowden
Analysis of the Harvey ras gene in cisplatin-initiated mouse skin tumors by polymerase chain reaction and direct DNA sequencing.
Cancer letters 1992;65(1):27-33.
1992: Mark A Nelson; Bernard W Futscher; T Kinsella; J Wymer; George Bowden
Detection of mutant Ha-ras genes in chemically initiated mouse skin epidermis before the development of benign tumors.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(14):6398-402.